Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $170,426.

  • China Pharma Holdings' Accumulated Expenses fell 86.43% to $170,426 in Q3 2025 from the same period last year, while for Sep 2025 it was $170,426, marking a year-over-year decrease of 86.43%. This contributed to the annual value of $247,159 for FY2024, which is 17.29% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Accumulated Expenses is $170,426, which was down 10.91% from $191,293 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 and a low of $110,387 during Q2 2022.
  • Over the past 3 years, China Pharma Holdings' median Accumulated Expenses value was $191,293 (recorded in 2025), while the average stood at $275,993.
  • As far as peak fluctuations go, China Pharma Holdings' Accumulated Expenses skyrocketed by 949.15% in 2024, and later plummeted by 86.43% in 2025.
  • China Pharma Holdings' Accumulated Expenses (Quarterly) stood at $298,452 in 2021, then skyrocketed by 35.64% to $404,807 in 2022, then dropped by 26.18% to $298,829 in 2023, then declined by 17.29% to $247,159 in 2024, then slumped by 86.43% to $170,426 in 2025.
  • Its Accumulated Expenses was $170,426 in Q3 2025, compared to $191,293 in Q2 2025 and $195,264 in Q1 2025.